Skip to main content

Advertisement

Log in

Adjusting Fracture Probability by Trabecular Bone Score

  • Original Research
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

The aim of the present study was to determine the impact of trabecular bone score on the probability of fracture above that provided by the clinical risk factors utilized in FRAX. We performed a retrospective cohort study of 33,352 women aged 40–99 years from the province of Manitoba, Canada, with baseline measurements of lumbar spine trabecular bone score (TBS) and FRAX risk variables. The analysis was cohort-specific rather than based on the Canadian version of FRAX. The associations between trabecular bone score, the FRAX risk factors and the risk of fracture or death were examined using an extension of the Poisson regression model and used to calculate 10-year probabilities of fracture with and without TBS and to derive an algorithm to adjust fracture probability to take account of the independent contribution of TBS to fracture and mortality risk. During a mean follow-up of 4.7 years, 1754 women died and 1639 sustained one or more major osteoporotic fractures excluding hip fracture and 306 women sustained one or more hip fracture. When fully adjusted for FRAX risk variables, TBS remained a statistically significant predictor of major osteoporotic fractures excluding hip fracture (HR/SD 1.18, 95 % CI 1.12–1.24), death (HR/SD 1.20, 95 % CI 1.14–1.26) and hip fracture (HR/SD 1.23, 95 % CI 1.09–1.38). Models adjusting major osteoporotic fracture and hip fracture probability were derived, accounting for age and trabecular bone score with death considered as a competing event. Lumbar spine texture analysis using TBS is a risk factor for osteoporotic fracture and a risk factor for death. The predictive ability of TBS is independent of FRAX clinical risk factors and femoral neck BMD. Adjustment of fracture probability to take account of the independent contribution of TBS to fracture and mortality risk requires validation in independent cohorts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129

    Google Scholar 

  2. Bala Y, Zebaze R, Ghasem-Zadeh A et al (2014) Cortical porosity identifies women with osteopenia at increased risk for forearm fractures. J Bone Miner Res 26:1356–1362

    Article  Google Scholar 

  3. Diez-Perez A, Gonzalez-Macias J, Marin F et al (2007) Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasound. Osteoporos Int 18:629–639

    Article  CAS  PubMed  Google Scholar 

  4. Faulkner KG, Cummings SR, Black D, Palermo L, Gluer CC, Genant HK (1993) Simple measurement of femoral geometry predicts hip fracture: the study of osteoporotic fractures. J Bone Miner Res 8:1211–1217

    Article  CAS  PubMed  Google Scholar 

  5. Gluer CC (2007) Quantitative Ultrasound—it is time to focus research efforts. Bone 40:9–13

    Article  PubMed  Google Scholar 

  6. Guerri-Fernandez RC, Nogues X, Quesada Gomez JM et al (2013) Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. J Bone Miner Res 28:162–168

    Article  CAS  PubMed  Google Scholar 

  7. Yang L, Peel N, Clowes JA, McCloskey EV, Eastell R (2009) Use of DXA-based structural engineering models of the proximal femur to discriminate hip fracture. J Bone Miner Res 24:33–42

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Keaveny TM, Kopperdahl D, Melton L et al (2010) Age-dependence of femoral strength in white women and men. J Bone Miner Res 25:994–1001

    Article  PubMed Central  PubMed  Google Scholar 

  9. Randall C, Bridges D, Guerri R et al (2013) Applications of a new handheld reference point indentation instrument measuring bone material strength. J Med Device 7:410051–410056

    Article  PubMed  Google Scholar 

  10. Silva BC, Leslie WD, Resch H et al (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 29:518–530

    Article  PubMed  Google Scholar 

  11. Kanis JA on behalf of the World Health Organization Scientific Group. 2007 Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK

  12. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Kanis JA, Johansson H, Oden A, Cooper C, McCloskey EV, Epidemiology and Quality of Life Working Group of IOF (2013) Worldwide uptake of FRAX. Arch Osteoporos 8:166

    Article  Google Scholar 

  14. Leslie WD, Metge C (2003) Establishing a regional bone density program: lessons from the Manitoba experience. J Clin Densitom 6:275–282

    Article  PubMed  Google Scholar 

  15. Leslie WD, Caetano PA, Macwilliam LR, Finlayson GS (2005) Construction and validation of a population-based bone densitometry database. J Clin Densitom 8:25–30

    Article  PubMed  Google Scholar 

  16. Leslie WD, Johansson H, Kanis JA et al (2014) Lumbar spine texture enhances ten-year fracture probability assessment. Osteoporos Int 25:2271–2277

    Article  CAS  PubMed  Google Scholar 

  17. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 27:1243–1251

    Article  CAS  PubMed  Google Scholar 

  18. Leslie WD, Tsang JF, Caetano PA, Lix LM (2007) Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 92:77–81

    Article  CAS  PubMed  Google Scholar 

  19. Lix LM, Azimaee M, Osman BA et al (2012) Osteoporosis-related fracture case definitions for population-based administrative data. BMC Public Health 12:301

    Article  PubMed Central  PubMed  Google Scholar 

  20. Looker AC, Wahner HW, Dunn WL et al (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468–489

    Article  CAS  PubMed  Google Scholar 

  21. Hans D, Goertzen AL, Krieg MA, Leslie WD (2011) Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res 26:2762–2769

    Article  PubMed  Google Scholar 

  22. Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046

    Article  CAS  PubMed  Google Scholar 

  23. Kanis JA, McCloskey EV, Johansson H, etal. 2008 Case finding for the management of osteoporosis with FRAX®—Assessment and intervention thresholds for the UK. Osteoporos Int 19: 1395–1408 Erratum 2009 Osteoporos Int 20, 499–502

  24. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2011) Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 22:839–847

    Article  CAS  PubMed  Google Scholar 

  25. Johansson H, Kanis JA, Odén A et al (2014) Impact of femoral neck and lumbar spine BMD discordances on FRAX probabilities in women: a meta-analysis of international cohorts. Calcif Tissue Int 95:428–435

    Article  CAS  PubMed  Google Scholar 

  26. Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809–816

    Article  CAS  PubMed  Google Scholar 

  27. National Osteoporosis Guideline Group. http://www.shef.ac.uk/NOGG/result-nobmd.html?age=65&fracture1=14&glucocorticoids=1. Accessed 7 Oct 2014

  28. Leslie WD, Lix LM, Johansson H et al (2010) Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res 25:2350–2358

    Article  PubMed  Google Scholar 

  29. Krieg MA, Aubry-Rozier B, Hans D et al (2013) Effects of antiresorptive agents on trabecular bone score (TBS) in older women. Osteoporos Int 24:1073–1078

    Article  CAS  PubMed  Google Scholar 

  30. Popp AW, Guler S, Lamy O et al (2013) Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study. J Bone Miner Res 28:449–454

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors acknowledge the Manitoba Centre for Health Policy (MCHP) for use of data contained in the Population Health Research Data Repository (HIPC Project Number 2012/2013-18). The results and conclusions are those of the authors, and no official endorsement by the MCHP, Manitoba Health, or other data providers is intended or should be inferred. The results and conclusions are those of the authors, and no official endorsement by Manitoba Health is intended or should be inferred. This article has been reviewed and approved by the members of the Manitoba Bone Density Program Committee.

Conflict of interest

E McCloskey: Nothing to declare for FRAX and the context of this paper, but numerous ad hoc consultancies/speaking honoraria and/or research funding from Amgen, Bayer, General Electric, GSK, Hologic, Lilly, Merck Research Labs, Novartis, Novo Nordisk, Nycomed, Ono, Pfizer, ProStrakan, Roche, Sanofi-Aventis, Servier, Tethys, UBS and Warner-Chilcott. H. Johansson and A. Oden declare that they have no conflict of interest. N. C. Harvey: Nothing to declare for FRAX and the context of this paper, but consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare and Internis Pharma. W. D. Leslie: Speaker bureau: Amgen, Eli Lilly, Novartis. Research grants: Amgen, Genzyme. Didier Hans: Co-ownership in the TBS patent. Stock options or royalties: Med-Imaps. Research grants: Amgen, Eli Lilly. JA. Kanis: Nothing to declare for FRAX and the context of this paper, but numerous ad hoc consultancies for: Industry: Abiogen, Italy; Amgen, USA, Switzerland and Belgium; Bayer, Germany; Besins-Iscovesco, France; Biosintetica, Brazil; Boehringer Ingelheim, UK; Celtrix, USA; D3A, France; Gador, Argentina; General Electric, USA; GSK, UK, USA; Hologic, Belgium and USA; Kissei, Japan; Leiras, Finland; Leo Pharma, Denmark; Lilly, USA, Canada, Japan, Australia and UK; Merck Research Labs, USA; Merlin Ventures, UK; MRL, China; Novartis, Switzerland and USA; Novo Nordisk, Denmark; Nycomed, Norway; Ono, UK and Japan; Parke-Davis, USA; Pfizer USA; Pharmexa, Denmark; Roche, Germany, Australia, Switzerland, USA; Rotta Research, Italy; Sanofi-Aventis, USA; Schering, Germany and Finland; Servier, France and UK; Shire, UK; Solvay, France and Germany; Strathmann, Germany; Tethys, USA; Teijin, Japan; Teva, Israel; UBS, Belgium; Unigene, USA; Warburg-Pincus, UK; Warner-Lambert, USA; Wyeth, USA Governmental and NGOs: National Institute for health and clinical Excellence (NICE), UK; International Osteoporosis Foundation; INSERM, France; Ministry of Public Health, China; Ministry of Health, Australia; National Osteoporosis Society (UK); WHO.

Human and Animal Rights and Informed Consent

The study was approved by the Research Ethics Board for the University of Manitoba and the Health Information Privacy Committee of Manitoba Health.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John A. Kanis.

Appendices

Appendix 1

The following method estimating the difference between probability of fracture with and without TBS avoids probability values outside the range 0–100. The inverse of the logistic function was used for each probability, i.e., −log(100/p − 1), where p is the 10-year probability in  %. Let us call this quantity for W1 when calculated for the 10-year probability including TBS and W0 for the probability without TBS. Now W1 will be the dependent variable of a multivariable regression analysis. Independent variables are age, TBS, age·TBS, and W0. We will find an estimated mean of W1 as a function of TBS, age, and W0. Let us call this estimated mean Z(W1, TBS, age) or shortly Z. Now we calculate 100/(1 + exp(−Z)), which is always a number in the interval 0–100. The number is our estimate of the 10-year probability including TBS. Again we can replace W0 for the corresponding number calculated (by the inverse of the logistic function) from the FRAX probability.

Appendix 2

The adjustment of fracture probabilities according to TBS is given for the 10-year probabilities of hip fracture and major osteoporotic fracture are given below

Outcome: Hip fracture

The 10-year probability calculated with TBS is \(\frac{100}{{1 + e^{ - w} }},\) where W = 15.420 − 12.627 × TBS − 0.194 × age + 0.157 × TBS × age + 0.920 × L, L = −ln(100/p  1), p is the 10-year probability calculated without TBS

Outcome: Major Osteoporotic Fracture

The 10-year probability calculated with TBS is \(\frac{100}{{1 + e^{ - w} }},\) where W = 5.340 − 4.213 × TBS − 0.0521 × age + 0.0393 × TBS × age + 0.897 × L, L = −ln(100/p − 1), p is the 10-year probability calculated without TBS

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCloskey, E.V., Odén, A., Harvey, N.C. et al. Adjusting Fracture Probability by Trabecular Bone Score. Calcif Tissue Int 96, 500–509 (2015). https://doi.org/10.1007/s00223-015-9980-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-015-9980-x

Keywords

Navigation